Literature DB >> 31204042

Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.

Xiao-He Hou1, Yan-Lin Bi2, Meng-Shan Tan1, Wei Xu1, Jie-Qiong Li1, Xue-Ning Shen1, Kai-Xin Dou1, Chen-Chen Tan1, Lan Tan1, Jin-Tai Yu3.   

Abstract

The triggering receptor expressed on myeloid cells 2 (TREM2) gene has been reported to increase the risk of Alzheimer's disease (AD). The soluble TREM2 protein (sTREM2) in cerebrospinal fluid (CSF) was also associated with AD. However, the role of sTREM2 in AD and its genetic modifiers remain unclear. We carried out a genome-wide association study for CSF sTREM2 levels using participants from the Alzheimer's Disease Neuroimaging Initiative and validated the significant association in an independent cohort from Chinese Alzheimer's Biomarker and LifestylE study. rs7232 in membrane spanning 4-domains A6A (MS4A6A) gene was associated with CSF sTREM2 levels at genome-wide significance (p = 1.42 × 10-15). The locus influences CSF sTREM2 levels especially in nondemented individuals. And the association was replicable in the validation cohort from Chinese Alzheimer's Biomarker and LifestylE study (p = 0.0106). Besides, the expressions of MS4A6A and TREM2 were correlated in brain regions (p < 2 × 10-16). The findings of our study suggest that the AD risk variant in the MS4A6A gene participates in the regulation of sTREM2.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Genome-wide association study; MS4A6A; TREM2

Year:  2019        PMID: 31204042     DOI: 10.1016/j.neurobiolaging.2019.05.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  8 in total

1.  Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease.

Authors:  Changan Liu; Jun Yu
Journal:  Front Aging Neurosci       Date:  2019-10-25       Impact factor: 5.750

2.  Associations of sleep characteristics with alpha-synuclein in cerebrospinal fluid in older adults.

Authors:  Xiao-Tong Wang; Feng-Tao Liu; Yan-Lin Bi; Xue-Ning Shen; Wei Xu; Jian Wang; Lan Tan; Jin-Tai Yu
Journal:  Ann Clin Transl Neurol       Date:  2020-09-19       Impact factor: 4.511

3.  Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.

Authors:  David Vogrinc; Katja Goričar; Vita Dolžan
Journal:  Front Aging Neurosci       Date:  2021-03-18       Impact factor: 5.750

4.  Anaemia and cerebrospinal fluid biomarkers of Alzheimer's pathology in cognitively normal elders: the CABLE study.

Authors:  Xin-Yu Yang; Xiao-He Hou; Yan-Lin Bi; Hao Hu; Xi-Peng Cao; Lan Tan; Jiu-Long Yang; Jin-Tai Yu
Journal:  BMC Neurol       Date:  2021-11-19       Impact factor: 2.474

Review 5.  Does Soluble TREM2 Protect Against Alzheimer's Disease?

Authors:  Guy C Brown; Peter St George-Hyslop
Journal:  Front Aging Neurosci       Date:  2022-01-28       Impact factor: 5.750

Review 6.  Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease.

Authors:  Chao Gao; Xin Shen; Yuyan Tan; Shengdi Chen
Journal:  J Neuroinflammation       Date:  2022-09-04       Impact factor: 9.587

Review 7.  The Genetics of Alzheimer's Disease in the Chinese Population.

Authors:  Chen-Ling Gan; Tao Zhang; Tae Ho Lee
Journal:  Int J Mol Sci       Date:  2020-03-30       Impact factor: 5.923

Review 8.  Advances in Genetics and Epigenetic Alterations in Alzheimer's Disease: A Notion for Therapeutic Treatment.

Authors:  Rubén Rabaneda-Bueno; Beatriz Mena-Montes; Sara Torres-Castro; Norma Torres-Carrillo; Nora Magdalena Torres-Carrillo
Journal:  Genes (Basel)       Date:  2021-12-08       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.